Device
Endovenous Laser Ablation (EVLA)
Endovenous Laser Ablation (EVLA) is a medical device with 3 clinical trials. Historical success rate of 100.0%.
Total Trials
3
Max Phase
—
Type
DEVICE
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 3 completed trials
Completion Rate
100%(3/3)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Phase Distribution
Ph not_applicable
3
100%
Phase Distribution
0
Early Stage
0
Mid Stage
0
Late Stage
Phase Distribution3 total trials
N/ANon-phased studies
3(100.0%)
Highest Phase Reached
UnknownTrial Status & Enrollment
Completion Rate
100.0%
3 of 3 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
3
all time
Status Distribution
Completed(3)
Detailed Status
Completed3
Development Timeline
Analytics
Development Status
Total Trials
3
Active
0
Success Rate
100.0%
Most Advanced
N/A
Trials by Phase
N/A3 (100.0%)
Trials by Status
completed3100%
Recent Activity
0 active trials
Showing 3 of 3
completednot_applicable
RCT Comparing EVLA Versus Polidocanol Foam in the Treatment of SSV Insufficiency
NCT05468450
completednot_applicable
The Effect of Laser Power and Fiber Traction Speed on the Outcomes of Endovenous Laser Ablation
NCT03037827
completednot_applicable
Clinical Trial of Endovenous 940 and 1470 Laser Ablation for Treating Great Saphenous Veins
NCT01637181
Clinical Trials (3)
Showing 3 of 3 trials
NCT05468450Not Applicable
RCT Comparing EVLA Versus Polidocanol Foam in the Treatment of SSV Insufficiency
NCT03037827Not Applicable
The Effect of Laser Power and Fiber Traction Speed on the Outcomes of Endovenous Laser Ablation
NCT01637181Not Applicable
Clinical Trial of Endovenous 940 and 1470 Laser Ablation for Treating Great Saphenous Veins
All 3 trials loaded
Drug Details
- Intervention Type
- DEVICE
- Total Trials
- 3